Overview

Cilengitide in Treating Patients With Acute Myeloid Leukemia

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well cilengitide works in treating patients with acute myeloid leukemia. Cilengitide may stop the growth of cancer cells by blocking the enzymes necessary for their growth
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)